News

I Have Parkinson’s: A Range of Voices (Opinion Letters)

The New York Times
October 17, 2025

In response to a NYTimes article about Dr. Sue Goldie, a Harvard professor who revealed her Parkinson's disease diagnosis, Parkinson's Foundation Chief Medical Officer, Sneha Mantri, MD, MS, FAA, submitted a letter to the editor to discuss access to care for the more than 90,000 Americans diagnosed annually.

News

Medications to Avoid with Parkinson’s Disease

Health Central
October 8, 2025

Parkinson's Foundation Chief Medical Officer Sneha Mantri, MD, and Foundation National Medical Advisor, Michael Okun, MD, are exclusively interviewed about medication protocols when taking levodopa or other Parkinson’s drugs.

News

The hidden trigger behind Parkinson’s has finally been spotted

BBC Science Focus
October 1, 2025

Scientists have, for the first time, directly visualized and counted alpha-synuclein oligomers, never seen before in brain tissue. The findings mark a major advancement in our understanding of PD.

News

How Gene Mutations Drive Dementia in Parkinson’s Disease

Yale School of Medicine
September 27, 2025

The Parkinson's Foundation supported new research recently published in a Nature Communications study that found cognitive deficits in Parkinson’s disease arise through a different—and unexpected—mechanism.

News

Hospitalized Parkinson’s disease patients who stay active may recover faster, have improved care outcomes, study finds

McKnights Long-Term Care News
September 18, 2025

People with Parkinson’s disease who remain active during their hospital stays may experience a faster recovery and better longevity, according to a study published in the June edition of Parkinsonism & Related Disorders. The Foundation's Hospital Care Recommendations are cited and Parkinson.org is linked.

News

Drug aiming to protect brain cells enters clinical trials

Parkinson's UK
September 8, 2025

Parkinson's Virtual Biotech-funded NRG Therapeutics has secured an impressive £50 million to advance their drug, NRG5051, into clinical trials for people with Parkinson’s and amyotrophic lateral sclerosis (ALS) , also known as motor neuron disease (MND). The Foundation is mentioned as a partner of the Parkinson's Virtual Biotech.